Dew, I think you are right. I remember already in 2003 Infigen had to send home most of its staff due to a lack of revenues. In July 2004 Pharming bought all licenses from Infigen, which related to their outstanding collaboration (see below). In fact, I thought Infigen didn't exist anymore, but they must have been surviving in the hope that their IP might become interesting for third parties, so they could make a restart. It is sad to see that early innovators do not make it.
"Pharming has obtained worldwide, non-exclusive, royalty-free, non-terminable licenses from Infigen for patents on nuclear transfer and associated technologies. The new licensing agreement will replace earlier agreements between the companies. The financial terms of the agreement with Infigen were undisclosed and has been approved by the Board of Supervisory Directors. Infigen will also relinquish claims to any milestone payments for product development as defined under earlier agreements."
[In a transaction about a year ago (#msg-16886410), ACTC acquired the IP in question from Infigen, which is now a shell company. Insofar as GTC does not have any cattle-based programs, Pharming’s license from ACTC would appear to be irrelevant for GTC. GTC already has freedom to operate using nuclear transfer by virtue of its license from Geron (#msg-19226707).]
>> Pharming Concludes License Agreement With Advanced Cell Technology
Leiden, The Netherlands, February 28, 2008. Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) announced today that it has concluded a license agreement with Advanced Cell Technology Inc to obtain exclusive rights on patents in the field of transgenic technology, to which it already had non-exclusive rights. Financial details of the agreement were not disclosed.
These patents were previously owned by Infigen Inc and cover a wide range of technologies including for Pharming relevant elements of nuclear transfer, which is an essential step in generating transgenic cattle. The agreement provides Pharming strict control over the generation of its transgenic cattle, while, at the same time, increasing the barriers of entry for others.
Protecting its technology platforms via patents and licenses is an essential element of Pharming’s strategy. This is done not only to maintain ‘freedom to operate’, but also to limit others in using the technology without a license, thereby protecting the investments that Pharming has made in developing its technology. <<
Market Data 
Markets 
AI
